ProNAi Therapeutics, Inc. (NASDAQ:SRRA) Rating Increased to Hold at Zacks Investment Research
Zacks Investment Research upgraded shares of ProNAi Therapeutics, Inc. (NASDAQ:SRRA) from a sell rating to a hold rating in a research report released on Wednesday, July 12th.
According to Zacks, “Sierra Oncology, Inc. is a clinical-stage drug development company. It develops and markets drugs for the treatment of cancer. The product pipeline consists of SRA737 and SRA141. SRA737 is an orally bioavailable small molecule inhibitor of Checkpoint kinase 1, a key cell cycle checkpoint and central regulator of the DNA Damage Response network. SRA141 is an orally available small molecule inhibitor of cell division cycle 7kinase. Sierra Oncology, Inc., formerly known as ProNAi Therapeutics, Inc., is headquatered in Vancouver, Canada. “
ProNAi Therapeutics (NASDAQ:SRRA) traded down 1.32% during trading on Wednesday, hitting $1.50. The stock had a trading volume of 208,932 shares. The company’s market capitalization is $78.40 million. ProNAi Therapeutics has a 12-month low of $1.10 and a 12-month high of $2.07. The stock has a 50 day moving average price of $1.25 and a 200 day moving average price of $1.35.
ProNAi Therapeutics (NASDAQ:SRRA) last announced its quarterly earnings results on Tuesday, May 9th. The biotechnology company reported ($0.26) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.19) by $0.07. Equities research analysts forecast that ProNAi Therapeutics will post ($0.90) earnings per share for the current year.
WARNING: This piece of content was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece of content on another site, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/08/07/pronai-therapeutics-inc-nasdaqsrra-upgraded-to-hold-by-zacks-investment-research-updated-updated-updated.html.
Several hedge funds have recently made changes to their positions in SRRA. Frazier Management LLC acquired a new stake in shares of ProNAi Therapeutics during the first quarter worth approximately $12,412,000. Perceptive Advisors LLC acquired a new stake in shares of ProNAi Therapeutics during the first quarter worth approximately $5,667,000. Sabby Management LLC acquired a new stake in shares of ProNAi Therapeutics during the first quarter worth approximately $2,672,000. PNC Financial Services Group Inc. acquired a new stake in shares of ProNAi Therapeutics during the first quarter worth approximately $1,142,000. Finally, Nexthera Capital LP purchased a new stake in ProNAi Therapeutics during the first quarter worth $612,000. Institutional investors own 60.30% of the company’s stock.
About ProNAi Therapeutics
Sierra Oncology, Inc, formerly ProNAi Therapeutics, Inc, is a clinical-stage drug development company. The Company’s lead drug candidate, SRA737, is orally bioavailable small molecule inhibitor of Checkpoint kinase 1 (Chk1), a key cell cycle checkpoint and central regulator of the deoxyribonucleic acid (DNA) Damage Response (DDR) network.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Stock Ratings for ProNAi Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProNAi Therapeutics Inc. and related stocks with our FREE daily email newsletter.